Alpha-9 is Vienna-bound! Join us for knowledge exchange and networking at the European Association of Nuclear Medicine (#EANM23) meeting. #radiopharmaceuticals
Alpha-9 Oncology’s Post
More Relevant Posts
-
We’re thrilled to welcome industry veterans Jean-Jacques Bienaimé and Steven Stein, M.D., to our board of directors. Their extensive operational and clinical expertise will be instrumental in advancing our programs through clinical stages, significantly enhancing treatment options for those living with cancer. https://lnkd.in/eGvxh963
-
-
We’re pleased to announce we have dosed the first participant in our Phase 1 clinical trial evaluating 68Ga-A9-3202, a melanocortin 1 receptor (MC1R) targeting agent for the imaging of locally advanced or metastatic #melanoma. This is an important milestone for our company as we continue to advance our portfolio of therapeutic molecules into the clinic. Read more: https://lnkd.in/df9_Y-F4
-
-
Today we announced a long-term supply agreement with ITM Isotope Technologies Munich SE that provides Alpha-9 with ITM’s non-carrier-added Lutetium-177 (n.c.a. 177Lu) for Alpha-9’s Lutetium-based candidates for the treatment of cancer. Read more: https://lnkd.in/ektbV_pG
-
-
Today we announced a long-term supply agreement with NorthStar Medical Radioisotopes, LLC, providing Alpha-9 with NorthStar’s high purity non-carrier added (n.c.a.) Ac-225 to be used in our targeted #radiopharmaceutical programs for the treatment of solid and liquid tumors. Read more: https://lnkd.in/enZfyRZP
-
